7^th World Congress on Bioavailability & Bioequivalence: BA/BE Studies Summit August 29-31, 2016 Atlanta, Georgia, USA

George Perry is a neuroscientist recognized in the field of Alzheimer's disease research particularly for his work in oxidative stress. Dr. Perry has studied at many universities and holds multiple degrees including a Bachelor of Arts degree in Zoology from the University of California Santa Barbara and a PhD in Marine Biology from the University of California at San Diego. He is distinguished as one of the top Alzheimer’s disease researchers with over 1000 publications, more than 60,000 citations, one of the top 100 most-cited scientists in Neuroscience & Behavior and one of the top 25 scientists in free radical research. Dr. Perry is a Semmes Foundation Distinguished chair in Neurobiology and is an active participant in many other scientific associations. In addition, Perry is an Editor of numerous scientific journals including Journal of Alzheimer’s Disease which he founded in 1998. Today, Perry continues his love for research while working as Dean of the College of Sciences at The University of Texas at San Antonio.

His research is centered around Neurodegeneration. In particular, Dr. Perry focuses mostly on Alzheimer’s disease and the effects of oxidative stress on the disease as well as its effects on other neurodegenerative disorders.

After his PhD (1991) at Tirana University, in the topic of Ion-Selective-Electrodes (ISEs) designs and applications in clinical and environmental analysis, Dr. Merkoçi worked as postdoc at other European research centres and USA in the field of nanobiosensors and lab-on-a-chip technologies. His postdoc periods were followed by leading positions in several laboratories: (1997-2006) at Autonomous University of Barcelona and since 2006 in ICN2.He has published around 200 peer review research papers, is editor of books.Prof. Merkoçi serves also as scientific evaluator and member of panels of experts of various international governmental and nongovernmental agencies (FP EU, USA, various EU and other countries), member of scientific committee of various international congresses, director of several workshops and other scientific events and have been invited to give plenary lectures and keynote speeches in more than 80 occasions in various countries.

His research is focused on the design and application of cutting edge nanotechnology and nanoscience based biosensors.

Mr. Hitesh Shah has a Masters degree in Pharmacology and Diploma in Pharmacoeconomics with more than 15 years of rich experience in various facets of Pharmaceutical fields including BA/BE studies, Pre-clinical studies, Clinical Trials, Formulation and Regulatory Affairs. He has conducted more than 500 Pharmacokinetics studies with various study designs. He has successfully faced regulatory inspections from DCGI - India, UK MHRA, US FDA, EMA, ANVISA- Brazil, WHO, MCC- South Africa, MoH-Turkey and Israel- MOH. He has worked previously with Wellquest Clinical Research Organization, Macleods BA/BE centre, DIL Group (formerly duphar –Interfran Ltd.) and DMRI. He has international publications to his credit.

BA/BE studies, Pre-clinical studies, Clinical Trials, Formulation and Regulatory Affairs.

An industry veteran and formulation expert with over 18 years of experience in generic and NCE product development. He holds Master of Pharmacy (pharmaceutics) from India, Master of Science (M.Sc.) and Master of Business Administration(MBA) from North America. He is Director and Head of Formulations & Manufacturing in GVK Biosciences.He is a Member of USP Expert Panel.

Preclinical to commercialization of solid dosage forms Sustained release dosage forms Bio availability enhancement of poorly soluble APIs

Jim Jingjun Huang received his Ph.D. in Pharmaceutics from the University of the Sciences in Philadelphia (formerly Philadelphia College of Pharmacy and Sciences) under Joseph B. Schwartz. He has fifteen years of pharmaceutical R&D and management experience in preclinical, clinical, and market formulation development of a variety of oral and parenteral dosage forms through his industrial training and employment with Pfizer (formerly Wyeth), Baxter, AstraZeneca, and Roche. He had lead the formulation efforts in successfully transition of several compounds from discovery to clinical stage of Phase I-II, and commercialization of several speciality injectable products from conception to formulation, manufacturing, technical transfer and finally the market.

Dr. Huang’s research interests are centered on solubility/dissolution rate improvement and controlled delivery of poorly water-soluble drugs through nano/micro-particle and amorphous solid dispersion technology. His publications include studies on drug solubilization and controlled delivery in polymeric solid dispersion systems, amorphous drug delivery systems, controlled release, modeling and simulation, thermal and spectroscopic characterization of amorphous molecular dispersion, drug-polymer interactions and its significance on physical stability of amorphous drug, and micro/nano particulate dosage forms for use in parenteral routs, etc. He credits several publications at peer-reviewed international journals, presentations at international pharmaceutical conference, and patent publications. He has been invited to serve as a reviewer for Journal of Pharmaceutical Sciences, Internation of Pharmaceutics, Journal of Controlled Release, Drug development and Industrial Pharmacy, PDA Journal of Pharmaceutical Science and Technology, Molecular Pharmaceutics, and Pharmaceutical Research. Currently, he is a member of American Association of Pharmaceutical Scientists (AAPS) and American Chemical Society (ACS).

Senior Pharmaceutical/Biotechnology executive with experience in both early stage companies and large pharma.He received many awards.

Health care

Dr. Mewa Singh heads research and product development Meda Biotech llc. With over 24 years of experience in the field of biopharmaceuticals. He provides expertise in Biotechnology, product development and the pharmaceuticals business market. Over the time period of 24 years. He has successfully launched products for diagnostics, vaccines, nutraceuticals and nanomedicines. He has applied five patents and is founder of two biotech startups ( Meda Biotech llc and Nano Biotech (P) Ltd. He has performed at administrative and senior management positions which included Director of R&D, Chief Scientific Officer, and COO positions. He holds M.S. in Biochemistry, M Phil in Biochemistry , Microbiology and Immunology, and PhD in Microbiology and Immunology.. Developing over 160 Nanomedicines for Pharmaceuticals, Nutraceuticals and Agrochemicals, he has been working with the strength of conviction that a new concept of Hybrid drugs, is the solubility solution for insoluble drugs. His discovery of Hybrid-Nanoengineeringâ„¢could have real significant therapeutic value for patients. This belief gave birth to a process of continual discovery and innovation, allowing him to develop many innovative medicines. Since 2002, his company Meda Biotech has been working to commercialize a technology that could make the treatment of cancer, pain and inflammation, more effective and less harmful to patients.

Product development in the field of ADC and Nanomedicnes.

Obtained successively the MSc (1994) and PhD (1997) degree in Pharmacology and Toxicology from Cairo University, Egypt. He was a visiting scholar in 2002 at the Department of Veterinary Medicine of the Tokyo University of Agriculture and Technology. In 2003 and 2005 he was a postdoctoral Research Fellow at the Pharamcogenetics Research Institute, Central South University, ChangSha, China and the Pharmacogenetics Research Center, Inje University College of Medicine, Busan, Republic of Korea, respectively. He was a visiting Professor from 2005 to 2007 at the Natural Products Chemistry Laboratory, Chonnam National University, Gwangju, Republic of Korea, and Foreign Assistant Professor at the Department of Veterinary Pharmacology and Toxicology, College of Veterinary Medicine, Konkuk University, Seoul, Republic of Korea. In 2009 he was appointed as full-time Professor at the Department of Pharmacology, Faculty of Veterinary Medicine, Cairo University, Egypt. Presented several communications at national and international congresses, and published more than 140 articles in international peer reviewed journals. He received in 2009 an award of the Cairo University for the best scientist in Basic Sciences, and in 2011 the National Incentive Reward for Biotechnology and Agricultural Sciences and the Publication Award from Misr El-Khair foundation. In 2013; he became a Brain Pool Fellow at Biotechnology Research Center, College of Agriculture and Life Sciences, Chonnam National University, Gwangju, Republic of Korea. He is among the board members of several Journals; among them Biomedical Chromatography. He serves the Journal of Advanced Research, the official Journal of Cairo University, as a Managing as well as Associate Editor.

His field of interest is biomedical analysis.

He holds a degree in Masters in Instrumentation and Chemical Analysis (M.I.C.A) from Jiwaji University, Gwalior. Mr. Shukla has published more than 50 international publications and posters in the Bioanalytical field.

Bio analytic, Pharmacokinetics and Pharmaceutics for a number of Bioavailability, Bioequivalence, and Pharmacokinetic